Mizuho Securities analyst Salim Syed has maintained their bullish stance on ELVN stock, giving a Buy rating on March 17.
Salim Syed has given his Buy rating due to a combination of factors surrounding Enliven Therapeutics’ promising developments. The company has highlighted 2025 as a significant year, with expectations for a data update from their ELVN-001 Ph1a/b trial. This open-label trial allows the management team to access data as it becomes available, providing transparency and potentially positive insights that could act as a catalyst for the stock.
Furthermore, Enliven is planning for a pivotal trial to commence in 2026, with two design options under consideration that both present low technical risk. These strategic plans, combined with the ongoing data visibility, contribute to an optimistic outlook for the company’s future performance, justifying the Buy rating from Salim Syed.
Syed covers the Healthcare sector, focusing on stocks such as Vaxcyte, Cytokinetics, and BridgeBio Pharma. According to TipRanks, Syed has an average return of -6.7% and a 37.85% success rate on recommended stocks.
In another report released on March 17, LifeSci Capital also reiterated a Buy rating on the stock with a $38.00 price target.